Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.

被引：0
|
作者：
Fasola, CG [1 ]
Netto, GJ [1 ]
Christensen, LL [1 ]
Sanchez, EQ [1 ]
Molmenti, EM [1 ]
Gonwa, TA [1 ]
Goldstein, RM [1 ]
Levy, MF [1 ]
Klintmalm, GB [1 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1869
引用
收藏
页码：639A / 639A
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics of tacrolimus and mycophenolate mofetil (MMF) in live donor and deceased donor liver transplant recipients
    Jain, A.
    Venkatramanan, R.
    Kwong, T.
    Orloff, M.
    Abt, P.
    Kashyap, R.
    Tsoulfas, G.
    Mack, C.
    Batzol, P.
    Williamson, M.
    Bozorgzadeh, A.
    [J]. JOURNAL OF HEPATOLOGY, 2007, 46 : S60 - S60
  • [22] A randomized, double-blind comparative study of mycophenolate mofetil (MMF) and azathioprine (AZA),in combination with cyclosporine and corticosteroids in liver transplant recipients.
    Mamelok, RD
    Kalayoglu, M
    Klintmalm, G
    Langnas, AN
    Levy, GA
    McDiarmid, SV
    McMaster, P
    Merion, R
    Rabkin, JM
    Wang, WD
    Wiesner, RH
    [J]. HEPATOLOGY, 1999, 30 (04) : 222A - 222A
  • [23] Further analysis of the intravascular ultrasound data from the randomized mycophenolate mofetil (MMF) trial in heart transplant recipients.
    Kobashigawa, JA
    Tobis, J
    Mentzer, RM
    Valantine, HA
    Bourge, RC
    Smart, FW
    Miller, LW
    Gordon, RD
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 548 - 548
  • [24] Safety and efficacy of mycophenolate mofetil as monotherapy for adult living donor liver transplant recipients.
    Cho, Euna-Ho
    Suh, Kyung-Suk
    Shin, Woo Young
    Lee, Hae Won
    Cho, Jai Young
    Yi, Nam-Joon
    Kim, Won
    Yoon, Jung-Hwan
    Lee, Kuhn Uk
    [J]. LIVER TRANSPLANTATION, 2007, 13 (06) : S73 - S73
  • [25] Severe anemia with Sofosbuvir based therapy for Hepatitis C (HCV) recurrence post Liver transplantation on mycophenolate mofetil (MMF)
    Elsiesy, Hussien
    Ajlan, Aziza A.
    Aljedai, Ahmed
    Alarieh, Rania
    Al-Hamoudi, Waleed K.
    Alkortas, Delal
    Al Sebayel, Mohammed
    Broering, Dieter C.
    Abaalkhail, Faisal A.
    [J]. HEPATOLOGY, 2014, 60 : 702A - 703A
  • [26] Hepatitis C recurrence in liver transplant recipients
    Kizilisik, TA
    AlSebayel, M
    Hammad, A
    AlTraif, I
    Ramirez, CG
    Abdulla, A
    [J]. TRANSPLANTATION PROCEEDINGS, 1997, 29 (07) : 2875 - 2877
  • [27] Significant alterations of mycophenolate mofetil (MMF) pharmacokinetics in pediatric allogeneic stem cell transplant (AlloSCT) recipients: Alternate dosing is required in AlloSCT compared to solid organ autograft recipients.
    Bessmertny, O
    Harrison, L
    Osunkwo, I
    Wischhover, C
    Garvin, J
    George, D
    Del Toro, G
    Bradley, MB
    Cairo, MS
    [J]. BLOOD, 2002, 100 (11) : 418A - 419A
  • [28] Evaluation of the role of mofetil mycophenolate (MMF) in delaying progression of hepatitis C (HepC) recurrence following orthotopic liver transplantation (OLTX)
    Netto, G
    Fasola, C
    Parker, C
    Mattison, TL
    Jennings, L
    Molmenti, E
    Levy, M
    Goldstein, R
    Klintmalm, G
    [J]. MODERN PATHOLOGY, 2001, 14 (01) : 201A - 201A
  • [29] Evaluation of the role of mofetil mycophenolate (MMF) in delaying progression of hepatitis C (HepC) recurrence following orthotopic liver transplantation (OLTX)
    Netto, G
    Fasola, C
    Parker, C
    Mattison, TL
    Jennings, J
    Molmenti, E
    Levy, M
    Goldstein, R
    Klintmalm, G
    [J]. LABORATORY INVESTIGATION, 2001, 81 (01) : 201A - 201A
  • [30] Hepatitis C virus genotype 4 recurrence in Egyptian living donor liver transplant recipients.
    Yosry, A
    Doss, W
    Abdel-Bary, A
    Esmat, G
    El-Serafy, M
    Omar, E
    El-Tawil, A
    Ghaly, A
    Hosny, A
    Rifaat, S
    El-Gabaly, H
    Tanaka, K
    [J]. LIVER TRANSPLANTATION, 2005, 11 (07) : C19 - C19
12345